Abstract |
Syringomycin E (SR-E), a new antifungal produced by the bacterium Pseudomonas syringae pv. syringae, was evaluated in a murine vaginal candidiasis model. In one study, mice were treated intravaginally b.i.d. for 4 days with drug carrier, SR-E 2% in either PEG-400 or PEG- ointment, or 1% clotrimazole as a positive control. Quantitative vaginal cultures were taken prior to treatment on day 1 and on days 5, 6, and 7. Both formulations showed a reduction of yeast colonization in the vaginas on day 5 (P< or =0.06 and P< or =0.03 for SR-E/ PEG-400 and SR-E/PEG ointment, respectively) and SR-E/PEG ointment reduced the colonization on day 7 (P< or =0.06) when compared to carrier treated controls. In a second study, SR-E was formulated in Aquaphor at three higher concentrations of SR-E [3%, 6%, or 12% (w/v)]. SR-E showed dose-dependent efficacy. The 3% dose showed no effect while the 6% and 12% doses reduced the number of yeasts. The 12% dose showed a significant reduction on days 5 (P< or =0.01), 6 (P< or =0.06), and 7 (P< or =0.03) when compared with the drug carrier controls and on day 5 was more effective than clotrimazole (P< or =0.03). Clotrimazole did not significantly reduce the yeasts in the vagina until days 6 (P< or =0.01) and 7 (P< or =0.01) when compared to the drug carrier controls. No vaginal inflammatory response was evident by histological examination in uninfected animals treated with SR-E. No SR-E could be detected in plasma, kidney, or liver. SR-E (12%) was an effective treatment when compared to 1% clotrimazole.
|
Authors | K N Sorensen, A A Wanstrom, S D Allen, J Y Takemoto |
Journal | The Journal of antibiotics
(J Antibiot (Tokyo))
Vol. 51
Issue 8
Pg. 743-9
(Aug 1998)
ISSN: 0021-8820 [Print] England |
PMID | 9766466
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antifungal Agents
- Drug Carriers
- Peptides, Cyclic
- syringomycin E
- Clotrimazole
|
Topics |
- Animals
- Antifungal Agents
(blood, therapeutic use)
- Candidiasis, Vulvovaginal
(drug therapy)
- Chromatography, High Pressure Liquid
- Clotrimazole
(therapeutic use)
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Drug Carriers
- Female
- Liver
(drug effects)
- Mice
- Mice, Inbred ICR
- Peptides, Cyclic
(blood, therapeutic use)
|